Sign in

CIK 0001754068

  • Non-accelerated filer
  • Smaller reporting company

Kalaris Therapeutics, Inc.

Sign in to watch
Ticker
KLRS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
831971007
Phone
+1 650-249-2727
Business address
400 CONNELL DRIVE, SUITE 5500, BERKELEY HEIGHTS, NJ, 07922
Former names
Allovir, Inc., ViraCyte, Inc.
  1. 4 Grant or award Director acquired 35,000 shares (grant or award)
  2. 4 Grant or award Director acquired 35,000 shares (grant or award)
  3. 4 Grant or award Director acquired 35,000 shares (grant or award)
  4. 4 Grant or award Director acquired 35,000 shares (grant or award)
  5. 4 Planned sale Sinha Vikas sold 2,683 shares at an average $3.66 ($9,828)
  6. 4 Planned sale Chief Accounting Officer sold 697 shares at an average $3.67 ($2,556)
  7. 4 Planned sale Chief Executive Officer sold 8,408 shares at $3.71 ($31,183)
  8. 4 Derivatives Options or other derivatives
  9. 3 Insider Initial Statement of Ownership
  10. 4 Open-market sale Chief Executive Officer sold 5,122 shares at $6.63 ($33,935)
  11. 4 Grant or award Sinha Vikas acquired 157,500 shares (grant or award)
  12. 4 Grant or award General Counsel acquired 87,500 shares (grant or award)
  13. 4 Grant or award Chief Scientific Officer acquired 81,006 shares (grant or award)
  14. 4 Grant or award Chief Accounting Officer acquired 61,250 shares (grant or award)
  15. 4 Grant or award Chief Executive Officer acquired 332,500 shares (grant or award)
  16. 4 Open-market sale Sinha Vikas sold 6,537 shares at an average $5.09 ($33,287)
  17. 4 Open-market sale General Counsel sold 2,573 shares at an average $5.09 ($13,101)
  18. 4 Open-market sale Chief Accounting Officer sold 1,895 shares at an average $5.09 ($9,645)
  19. 4 Open-market sale Chief Executive Officer sold 34,435 shares at $5.08 ($174,851)
  20. 4 Open-market sale Chief Executive Officer sold 4,515 shares at $7.27 ($32,810)

Page 9 of 19 · 363 filings